Financial·Reported by 10 outside sources·
The company announced plans to begin registrational studies for its lead T-cell engager, gamgertamig, in 2027 following operational restructuring and asset acquisition.
- Who
- Lakefront Biotherapeutics
- Where
- United States (implied by NASDAQ listing)
- When
- Why
- Following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines.
via marketaux